Search all trials

Find therapies in clinical trials near you – page 5

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Lung disorder

Not recruiting

Registered drugNo placebo

Study on the Effectiveness of Osimertinib for Patients with EGFR Mutant Non-Small Cell Lung Cancer Based on TP53 Mutation Status

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Osimertinib

Contact Research Centre

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Avelumab

Contact Research Centre

Crohn's disease

Not recruiting

Registered drug

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Bi 706321

Contact Research Centre

Hormone-refractory prostate cancer+1

Not recruiting

Registered drugNo placebo

Study on Radium-223, Docetaxel, and Prednisone for Patients with Bone-Only Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Crohn's disease

Not recruiting

Investigational

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Guselkumab

Contact Research Centre

Crohn's disease

Not recruiting

Investigational

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Etrasimod Arginine

Contact Research Centre

Breast cancer

Not recruiting

Registered drugNo placebo

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide

Contact Research Centre

Malignant peritoneal neoplasm+2

Not recruiting

Registered drugNo placebo

Study of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Lung carcinoma cell type unspecified recurrent

Not recruiting

Registered drugNo placebo

Study of Durvalumab with Thoracic Radiotherapy and Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer After Initial Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Neovascular age-related macular degeneration

Not recruiting

Registered drugNo placebo

Study on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Aflibercept

Contact Research Centre

Breast cancer

Not recruiting

Registered drug

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Olaparib

Contact Research Centre

Breast cancer metastatic

Not recruiting

Registered drug

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Giredestrant

Contact Research Centre

Find therapies in clinical trials near you – page 5

70 trials match your criteria

Lung disorder

Study on the Effectiveness of Osimertinib for Patients with EGFR Mutant Non-Small Cell Lung Cancer Based on TP53 Mutation Status

Triple negative breast cancer

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Crohn's disease

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Hormone-refractory prostate cancer+1

Study on Radium-223, Docetaxel, and Prednisone for Patients with Bone-Only Metastatic Castration-Resistant Prostate Cancer

Crohn's disease

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Crohn's disease

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Breast cancer

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Malignant peritoneal neoplasm+2

Study of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Lung carcinoma cell type unspecified recurrent

Study of Durvalumab with Thoracic Radiotherapy and Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer After Initial Treatment

Neovascular age-related macular degeneration

Study on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration

Breast cancer

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Breast cancer metastatic

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.